SLDB: Advancing novel gene therapies for DMD and FA, with pivotal FDA meetings and data ahead
The company is advancing AAV gene therapies for DMD and FA, prioritizing these programs with novel constructs and delivery platforms. Key FDA meetings and data readouts are expected in the next two quarters, with a strong cash position supporting operations into 2028.Based on Solid Biosciences Inc…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.